-
Dan Boeglin - Outside Counsel
Dan Boeglin has more than 25 years' experience negotiating corporate transactions and advising Boards of Directors on legal and business matters.
Read MoreDan Boeglin - Outside Counsel
Dan Boeglin has more than 25 years' experience negotiating corporate transactions and advising Boards of Directors on legal and business matters.
Dan Boeglin has more than 25 years' experience negotiating corporate transactions and advising Boards of Directors on legal and business matters. For more than a decade, his practice has been focused almost exclusively in the life sciences industry; specifically, representing companies that develop, make and sell drugs and medical devices.
Mr. Boeglin has represented leading pharmaceutical, medical device and biotechnology companies, including li Lilly and Zimmer, in M&A, corporate partnering, joint venture, intellectual property licensing, venture capital and other transactions. He has been lead counsel in the formation of multi-party joint ventures in the fields of biomarker discovery, proteomics research and electronic health records.
Mr. Boeglin serves as outside general counsel to a number of emerging biotechnology companies. Earlier in his career, he was a founder and general counsel of Provalent, Inc., a venture-backed internet company, where he gained valuable business and legal experience that is particularly relevant to his emerging company practice. Mr. Boeglin is recognized as a leading lawyer in the areas of corporate and biotechnology law in The Best Lawyers in America and in Chambers USA: A Guide to America's Leading Business Lawyers. He has completed the Biotechnology for Business program at Duke University.
Mr. Boeglin graduated from the Indiana University Kelley School of Business in 1982 and from the University of Virginia School of Law in 1985. He has served the Kelley School of Business as President of its Alumni Association, as a member of its Dean's Advisory Council, and as a Board member of the Johnson Center for Entrepreneurship and Innovation.
-
Joe Broecker - Senior Financial Advisor
Mr. Broecker is a co-founder and Senior Managing Director of Periculum Capital Company, LLC and head of the firm's private equity and merchant banking practice.
Read MoreJoe Broecker - Senior Financial Advisor
Mr. Broecker is a co-founder and Senior Managing Director of Periculum Capital Company, LLC and head of the firm's private equity and merchant banking practice.
Mr. Broecker is a co-founder and Senior Managing Director of Periculum Capital Company, LLC and head of the firm's private equity and merchant banking practice.
He was previously a Senior Vice President and Managing Director of NatCity Investments, Inc., as well as its predecessor firm, Raffensperger, Hughes and Co. Mr. Broecker focused most of his practice on private equity and expansion financings for emerging growth and technology-based companies. He co-founded two venture capital private equity partnerships and remains an active advisor to private equity firms throughout the Midwest.
Mr. Broecker was a senior operating and corporate executive with a large European-based multi-national medical device and pharmaceutical company which involved the management of subsidiaries and divisions with an established market presence as well as new technology and start-up operations. Mr. Broecker was previously a manager in the consulting division of Ernst and Young (a/k/a Ernst & Ernst). He received an Executive MBA from Indiana University and a BBA in accounting and finance from the University of Notre Dame. Mr. Broecker is a CPA and has served as a director of a number of private and public companies primarily involved in the healthcare, chemical, and consumer industries.
-
Ralph F. Hall, JD - Senior Advisor to Phlebotics, Inc.
Intellectual Property, Regulatory and Legal ServicesRalph Hall, currently a University of Minnesota Law School Distinguished Professor and Practitioner, has had a distinguished and unique legal career focused on Food and Drug Administration (FDA) regulatory matters.
Read MoreRalph F. Hall, JD - Senior Advisor to Phlebotics, Inc.
Intellectual Property, Regulatory and Legal ServicesRalph Hall, currently a University of Minnesota Law School Distinguished Professor and Practitioner, has had a distinguished and unique legal career focused on Food and Drug Administration (FDA) regulatory matters.
Ralph Hall, currently a University of Minnesota Law School Distinguished Professor and Practitioner, has had a distinguished and unique legal career focused on Food and Drug Administration (FDA) regulatory matters. He received his JD at the University of Michigan but quickly left a litigation practice to assume sequential roles as corporate council for prestigious medical technology companies including Guidant, Eli Lilly, and Life Science Group. At the University of Minnesota, he teaches FDA courses along with courses in compliance and negotiations. He has published multiple articles and book chapters on FDA and compliance matters, particularly in the area of new technology such as nanotech. Mr. Hall served on the Board of Directors of the Food and Drug Institute, the Board of Editors of the Food and Drug law Journal and is former chair of the Food and Drug Law Institute's academic committee. He has published on compliance, oversight, and ethics of new orpediatric-specific technologies and is participating in 2 ongoing NIH-fundedstudies in these areas. His unique background makes him ideal to advise Phlebotics, Inc. on Intellectual Property, Regulatory and Legal Services. In addition, Mr. Hall has uniques experience with the best incentives for pediatric device innovation in the current financial market. The Phlebot is proposed to have unique opportunities for safety and efficacy in the pediatric clinical trials and ICU space.
-
Joerg Schreiber, Ph.D. - Operations Management
Nineteen years of experience in Life Sciences Industry with Roche
Read More
Diagnostics, formerly Boehringer Mannheim 1986 - 2005
Vice President Special Projects, Indianapolis 2003 - 2005Joerg Schreiber, Ph.D. - Operations Management
Nineteen years of experience in Life Sciences Industry with Roche
Diagnostics, formerly Boehringer Mannheim 1986 - 2005
Vice President Special Projects, Indianapolis 2003 - 2005Vice President R&D and Business Development MyDoc.com 2001 - 2003
Vice President of Patient Care R/D 1996 - 2001
Head of Process Development 1994 - 1995
Operations, Head of Core Services 1995 - 1996
Group Leader, Department Leader, Mannheim, Germany 1986 - 1994 -
Jon D. Speer - Project Coordinator - Outside Vendors
In 2006, Jon Speer founded Creo Quality to support life science start-ups with product development, project management, and operational needs. Jon has considerable experience in the medical device industry.
Read MoreJon D. Speer - Project Coordinator - Outside Vendors
In 2006, Jon Speer founded Creo Quality to support life science start-ups with product development, project management, and operational needs. Jon has considerable experience in the medical device industry.
In 2006, Jon Speer founded Creo Quality to support life science start-ups with product development, project management, and operational needs. Jon has considerable experience in the medical device industry. Previously, he worked in quality management, product and business development capacities for Cook, Inc., Theron, Inc., and Maetrics, LLC, leading and managing multiple projects, taking concepts through development, regulatory submission, and to the market. Additional areas of expertise include: corporate product development processes, personnel distribution, and portfolio management; helping implement FDA-compliant quality system procedures for multiple start-up organizations; and facilitating business development activities, including lead generation and business expansion.
CQ is prepared to be your foundation in the medical device industry. Our well-developed relationships within the industry allow us access to a solid association of life science resources, partners, and suppliers in Indiana that can help you reach your full potential.
-
-
Thomas G. Sors, PhD - Scientific Advisory Board
Thomas (Tommy) Sors is the Assistant Director of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D) where he helps drive the strategic direction and manage the daily operations of the Institute.
Read MoreThomas G. Sors, PhD - Scientific Advisory Board
Thomas (Tommy) Sors is the Assistant Director of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D) where he helps drive the strategic direction and manage the daily operations of the Institute.
Dr. Sors is responsible for forming research teams and helping them translate their research goals. In addition, Dr. Sors supports the Indiana Clinical and Translational Sciences Institute (CTSI), where he has established a reputation for connecting investigators from across the region to core facilities and research collaborators at Purdue University. Dr. Sors leadership in PI4D started in 2016 after serving in the Bindley Bioscience Center first as Center Project Manager and then as Chief Scientific Liaison. He received his Ph.D. degree in Plant Physiology and Molecular Biology from the Department of Horticulture at Purdue University in 2008 and remained at Purdue to complete his post-doctoral research in the Department of Biochemistry.
-
-
Prof. J. Paul Robinson - Scientific Advisory Board
J. Paul Robinson is the SVM Professor of Cytomics in the College of Veterinary Medicine and a professor of biomedical engineering at Purdue University.
Read MoreProf. J. Paul Robinson - Scientific Advisory Board
J. Paul Robinson is the SVM Professor of Cytomics in the College of Veterinary Medicine and a professor of biomedical engineering at Purdue University.
His lab has been funded by DARPA, NIH, NSF and the USDA as well as private industry. Over the past several years, his group has expanded their interest in bioengineering with hardware and software groups developing innovative advanced classification approaches for clinical diagnostics and bacterial classification. He summited Mt. Everest on May 23, 2009, (http://www.cyto.purdue.edu/trackpaul/) in his bid to raise awareness of the major issues facing those who are HIV positive particularly in Africa. The lack of low cost diagnostic tools has been an important focus of his laboratory activity over recent years.
-
-
Prof. David D. Koch, PhD, DABCC, FAACC - Scientific Advisory Board
David Koch, Ph.D. is currently a Professor of Pathology at Emory University School of Medicine and Director of Clinical Chemistry, Special Chemistry, Toxicology and Point-of-Care testing at Grady Memorial Hospital in Atlanta, Georgia.
Read MoreProf. David D. Koch, PhD, DABCC, FAACC - Scientific Advisory Board
David Koch, Ph.D. is currently a Professor of Pathology at Emory University School of Medicine and Director of Clinical Chemistry, Special Chemistry, Toxicology and Point-of-Care testing at Grady Memorial Hospital in Atlanta, Georgia.
Dr. Koch is a Diplomate of the American Board of Clinical Chemistry and an active member of the American Association for Clinical Chemistry, currently serving on the Board of Directors and as President. He is also an active member of the National Academy of Clinical Biochemistry, where he is the current Chair of the Awards Committee.
Dr. Koch, having earned both his B.S. in Chemistry and Ph.D. in Analytical Chemistry at Purdue University, completed his postdoctoral training in clinical chemistry at Washington University School of Medicine in the laboratory of Dr. Jack Ladenson. Prior to his current position Dr. Koch served as Director of the Clinical Chemistry Service at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin, and as the Associate Director of Clinical Pathology in Safety Assessment at the Merck Research Laboratories in West Point, Pennsylvania. Dr. Koch's service to the field of clinical chemistry has also included membership on CLSI Committees and Subcommittees.
-
-
David G. Kolasinski - Business Development Advisor
Dave has diversified health industry experience focusing on life sciences, diagnostics, devices and therapeutics.
Read MoreDavid G. Kolasinski - Business Development Advisor
Dave has diversified health industry experience focusing on life sciences, diagnostics, devices and therapeutics.
He has worked for companies that cover the process map from research and development through commercialization of a new technology or device. He has commercialized devices for immunology, serology, chemistry, coagulation, blood banking and microbiology. The companies where Alere (Abbott Labs), Matritech, a biotech start-up, Inproteo (Eli Lilly), FluorRx/Plastimed a biotech start-up, Boehringer Mannheim (Roche). Baxter Laboratories, Abbott and Amersham (GE). He has demonstrated leadership skills at the general management level, directing the activities of Sales, Marketing, Education, Finance, Production, Technical Support and Product Development. Business units with over $300 million in revenues all the way to a start-up seeking to commercialize its first device. He has worked with lobbyist to raise awareness in Washington as to the overall cost savings that are realized by appropriate utilization of diagnostics devices. He has directed reimbursement campaigns to get reasonable compensation for the physician so they can afford to use a new diagnostic device. Dave was the director for the 21st Century biotechnology senate bill (514) for the state of Indiana for bioscience investment. It was successful and $25 million was appropriated. He has been on several panels for the Health Industry Distributors Association (HIDA), Biomedical Marketing Association and IMDA.
